We use cookies, including third-party cookies from Google to serve personalized ads through AdSense, to operate this site and understand how it is used. By continuing to browse, you accept this use. See our Privacy Policy and Terms of Use for details, including how to opt out of personalized advertising.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: FDA Approves Roche (Genentech) Skin Cancer Drug–Zelboraf
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > FDA Approves Roche (Genentech) Skin Cancer Drug–Zelboraf
Business

FDA Approves Roche (Genentech) Skin Cancer Drug–Zelboraf

BarbaraDuck
BarbaraDuck
Share
3 Min Read
SHARE

Cancer drugs certainly are not cheap and for a year, this one is right up there with Provenge in cost with over 100k if it was prescribed for a year.  The diagnosis part of $150 is the easy financial part of this.  In the clinical trials though it was noted that some patients become resistant to the drug.  The approval came earlier than anticipated from the FDA based on the strong clinical data.  BD 

Cancer drugs certainly are not cheap and for a year, this one is right up there with Provenge in cost with over 100k if it was prescribed for a year.  The diagnosis part of $150 is the easy financial part of this.  In the clinical trials though it was noted that some patients become resistant to the drug.  The approval came earlier than anticipated from the FDA based on the strong clinical data.  BD 

U.S. drug regulators approved a targeted skin cancer drug from Roche Holding, offering new hope for patients with the deadliest form of imagecancer after years of few options.

The U.S. Food and Drug Administration was two months ahead of schedule in approving the drug, under the brand name Zelboraf, along with a companion diagnostic test that identifies which patients have a specific genetic mutation that means they will benefit from the treatment.

Zelboraf was developed in partnership with Daiichi Sankyo and is the second drug to be approved for melanoma this year, after Yervoy from Bristol-Myers Squibb

Roche said Zelboraf would cost about $56,400 for a six-month course of treatment in the United States. Bristol’s Yervoy costs $120,000 for a course of treatment. The diagnostic test will cost around $150, according to Paul Brown, president of Roche Diagnostics.

Side effects from Zelboraf include rash, slight hair loss, extreme photosensitivity and joint pain. Roche filed for U.S. approval of the drug in April and the FDA had to make a decision by Oct. 28. Reuters reported on Aug. 10 that an early nod was likely.

http://www.cnbc.com/id/44178560?__source=RSS*tag*&par=RSS

 

More Read

Healthcare Consumerism
Midwest Health Startups: Making More Deals but Drawing Less Money
Show Me the Money: Profitability Through Value-Based Purchasing
British National Health Service – HealthCare Within a Budget
Effective Incident Reporting Surrounding Patient Satisfaction

TAGGED:FDAhealthcare businessRoche Pharmaceuticalsskin cancerZelboraf
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

Flat editorial illustration: Healthcare volunteer communication as a two-way, coordinator-supported process for confirming schedu
How to Manage Volunteer Communication in Healthcare: 5 Tactical Steps and Software Options
Global Healthcare
November 18, 2026
The Nervous System Reset Guide: Simple Ways To Manage Stress -- AI-generated illustration
The Nervous System Reset Guide: Simple Ways To Manage Stress
Infographics Mental Health
November 14, 2026
Flat editorial illustration: A single digital quality-management platform connects document control, electronic approval, audit r
6 Best QMS Software Platforms for ISO 13485 and FDA Part 820 (QMSR)
Global Healthcare Policy & Law
November 12, 2026
Flat editorial illustration: Healthcare editorial illustration about accurate patient intake connecting registration, clinical re
The Role of Patient Data Accuracy in Healthcare Operations
Global Healthcare Policy & Law
November 11, 2026

You Might also Like

The Power of Conversations Between Physicians and Patients

March 17, 2014

OneMedForum NY 2011 Grows Its Advisory Board And Selects Initial Presenters

April 18, 2011

Healthcare Marketing and the Millennials

April 5, 2015

Hospitals not Leveraging Facebook

April 6, 2011
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2026 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?